

SAS:dsh 3/16/06 498790 1-009-98/1
PATENT

Attorney Reference Number 6395-59041-01
Application Number 09/889,317

Listing of Claims

1. (Currently Amended) A method for treating viral or bacterial-induced inflammation of the lung in a subject mediated by endogenous substance P, comprising nasally administering to the subject a pharmaceutically-effective amount of anti-substance P antibody fragments, thereby treating the viral or bacterial-induced inflammation of the lung in the subject.

2. (Canceled).

3. (Currently Amended) The method of Claim 1 wherein the inflammation of the lung is caused by a viral agent.

4. (Currently Amended) The method of Claim 3 wherein the inflammation of the lung is caused by respiratory syncytial virus.

5-12. (Canceled)

13. (Previously Presented) The method of Claim 1 wherein from about 0.5 mg to about 2 g per kilogram of body weight per day of the antibody fragments are administered to the subject.

14. (Previously Presented) The method of Claim 13 wherein from about 1 mg to about 1 g per kilogram of body weight per day of the antibody fragments are administered to the subject.

15-18. (Cancelled)

19. (Currently Amended) A method for preventing viral or bacterial-induced inflammation bronchiolitis in a subject mediated by endogenous substance P, comprising nasally administering to the subject a pharmaceutically-effective amount of anti-substance P antibody fragments, thereby preventing the viral or bacterial-induced inflammation bronchiolitis in the subject.

SAS:dsh 3/16/06 498790 1-009-98/1
PATENT

Attorney Reference Number 6395-59041-01
Application Number 09/889,317

20. (Canceled).

21. (Currently Amended) The method of Claim 19 wherein the ~~inflammation~~ bronchiolitis is caused by a viral agent.

22. (Currently Amended) The method of Claim 21 wherein the ~~inflammation~~ bronchiolitis is caused by respiratory syncytial virus.

23-30. (Cancelled)

31. (Previously Presented) The method of Claim 19 wherein from about 0.5 mg to about 2 g per kilogram of body weight per day of the antibody fragments are administered to the subject.

32. (Previously Presented) The method of Claim 31 wherein from about 1 mg to about 1 g per kilogram of body weight per day of the antibody fragments are administered to the subject.

33-36. (Cancelled)

37. (Previously Presented) The method of Claim 1 wherein anti-substance P F(ab')₂ antibody fragments are administered to the subject.

38. (Previously Presented) The method of Claim 19 wherein anti-substance P F(ab')₂ antibody fragments are administered to the subject.

39-40. (Cancelled)

41. (Previously Presented) A method for reducing the levels of intracellular cytokines in a subject with bacterial or viral induced inflammation of the lung, comprising nasally administering to the subject a pharmaceutically-effective amount of anti-substance P antibody fragments, thereby reducing the levels of intracellular cytokines in the T lymphocytes of the subject with bacterial or viral

SAS:dsh 3/16/06 498790 1-009-98/1
PATENT

Attorney Reference Number 6395-59041-01
Application Number 09/889,317

induced inflammation of the lung.

42. (Previously Presented) The method of Claim 41 wherein the cytokine is IL-2, IL-4, IL-6, or INF γ .

43-44. (Cancelled)